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Abstract The modulation of the gamma-aminobutyric acid
type A (GABA A) receptors activity was observed in
several chronic hepatitis failures, including hepatitis C. The
expression of GABA A receptor subunits α1 and β3 was
detected in peripheral blood mononuclear cells (PBMCs)
originated from healthy donors. The aim of the study was to
evaluate if GABA A α1 and β3 expression can also be
observed in PBMCs from chronic hepatitis C (CHC)
patients and to evaluate a possible association between
their expression and the course of hepatitis C virus (HCV)
infection. GABA A α1- and β3-specific mRNAs presence
and a protein expression in PBMCs from healthy donors
and CHC patients were screened by reverse transcription
polymerase chain reaction (RT-PCR) and Western blot,
respectively. In patients, HCV RNA was determined in sera
and PBMCs. It was shown that GABA A α1a n dβ3
expression was significantly different in PBMCs from CHC
patients and healthy donors. In comparison to healthy
donors, CHC patients were found to present an increase in
the expression of GABA A α1 subunit and a decrease in
the expression of β3 subunit in their PBMCs. The
modulation of α1 and β3 GABA A receptors subunits
expression in PBMCs may be associated with ongoing or
past HCV infection.
Introduction
The gamma-aminobutyric acid (GABA), the major inhibitory
neurotransmitter in the mammalian central nervous system,
causes changes in a polarization of cell membrane acting
through the activation of GABA receptors. The most
prevalent, GABA type A (GABA A), receptors tend to exist
aspentamericstructuresconsistingofvariouscombinationsof
six major subunits: α, β, γ, δ, ε,a n dπ [1]. Recent data
indicate that GABAergic activity is not restricted to the
central nervous system, but also involves cells of different
origin that, like hepatocytes, possess the peripheral type of
G A B AAr e c e p t o r s[ 2]. As was shown in several studies, an
activation of GABA A receptors (especially the β3s u b u n i t )
leads to the hyperpolarization of cell membrane, which, in
turn, causes a rapid decrease in cell proliferation [3, 4]. This
feature seems to be interesting with regard to the study that
demonstrated the impact of cell polarization on the efficiency
ofhepatitis Cvirus (HCV)entry [5]. An elevated GABAergic
activity was found to be responsible for the impaired
hepatocyte proliferation in regenerating livers after partial
hepatectomy [6, 7]. On the other hand, it has been known
since the early 1980s that the serum level of GABA may be
elevated in case of acute or chronic hepatocellular failure [8],
and the GABA neurotransmitter system is involved in the
pathogenesis of hepatic encephalopathy (HE) in humans [9].
Recently, it has been suggested that HE-dependent ammonia
may be developed due to the modification of the GABA A
receptor affinity [10]. Other findings suggest that increased
inhibition through GABA A receptors may represent an
important pathophysiological mechanism of fatigue in
chronic HCV infection [11].
This multifunctionality of GABAergic action in numerous
liver failureshasdrawnourattentiontothe possibleroleofthe
modulation of GABA A receptors expression in the course of
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Although the liver is the main place of HCV replication,
gathered data, including our own [12, 13], indicate that HCV
can persist and replicate efficiently in extrahepatic tissue,
including peripheral blood mononuclear cells (PBMCs).
HCV RNA can persist in PBMCs long after spontaneous
or treatment-induced viral elimination from sera [14], but the
relevance of this phenomenon is still unknown. It has been
documented recently that PBMCs originated from the
healthy human population express functional α1a n dβ3
subunits of the GABA A receptor [15]. The aim of the
current study was to investigate whether the comparable
expression of GABA A subunits can be observed in PBMCs
from chronic hepatitis C (CHC) patients that have undergone
anti-HCV treatment. Consequently, not only did we succeed
to show α1a n dβ3 expression in PBMCs from HCV-
infected patients, but our results also demonstrated the
substantial differences in β3a n d ,l e s sm a n i f e s t e d ,i nα1
subunits expression in PBMCs between healthy donors and
post-treatment HCV patients. We then speculate on how the
alterations in the expression of GABA A subunits may be of
special importance for HCV RNA persistence.
Materials and methods
Blood samples were collected, after the informed consent had
been obtained, from ten healthy donors (6 males, 4 females:
age 18–26 years) and from 22 chronically infected with HCV
patients (12 males, 10 females: age 16–22 years) within
2weeksafterthecessation ofantiviraltreatment(IFNalfa2b+
ribavirin). Neither patients nor healthy controls were taking
medication known to alter GABA A receptor expression or
activity.PBMCsandserawereisolatedbybloodcentrifugation
in density gradient (Histopaque 1077, Sigma). Total RNA
was extracted from PBMCs by a modified guanidinium
thiocyanate/phenol/chloroform technique.
HCV RNA presence in sera was determined by reverse
transcription polymerase chain reaction (RT-PCR) (Cobas,
Amplicor HCV 2.0 Monitor, Roche). HCV RNA in
PBMCs was detected by RT-PCR as described previously
[13]. Briefly, 6 μg of total RNA were reverse-transcribed
and amplified by MasterAmp™ Tth DNA Polymerases
(Epicentre® Biotechnologies) with external HCV-specific
primers (Table 1) in a reaction as follows: 20 min of RT at
70°C and 3 min at 94°C, followed by 35 cycles of 94°C for
20s, 50°C for 20s, 72°C for 20s, and 72°C for 7 min. The
resultant amplicon was used in the second-round PCR
(2 min at 94°C, 30 cycles of 94°C for 40s, 55°C for 40s,
72°C for 40s, and 72°C for 10 min). After PA gel
electrophoresis, an HCV-specific product of 278 bp was
visualized with ethidium bromide staining.
For the detection of mRNAs specific for GABA A
receptor subunits α1 and β3, random cDNA was synthe-
sized according to the manufacturer’s instructions by using
the Transcription High Fidelity cDNA Synthesis Kit (Roche
Diagnostics, Mannheim, Germany) and then amplified in
“nested” PCR [15] with gene-specific primers (Table 1).
The expression analysis of actin was used as an internal
control for each sample. PCR assays (each of 35 cycles)
were performed as follows: 5 min of preliminary heating at
94°C, 94°C for 40s, 50°C (for GABA A α1/β3)/55°C (for
actin) for 40s, 72°C for 40s, and 72°C for 10 min. PCR α1-
and β3-specific products of 95 bp and 110 bp, respectively,
were analyzed as described above.
GABA A α1 and β3 subunit expression was determined
by Western blotting. Protein lysates (20 μg/lane) were
separated on 10% SDS-PA gel. Resolved proteins were
electroblotted into nitrocellulose and incubated with GABA
A α1, 52 kDa (GTX 30204, dilution 1:12,000 ) and β3,
Table 1 List and sequences
of primers used in the reverse
transcription polymerase chain
reaction (RT-PCR) analysis
and size of PCR products
Specificity of primers PCR product (bp) Sequence of forward and reverse primers
HCV RNA (external) 321 F: CCACCATGAATCACTCCCCTGT
R: GCTCATGGTGCACGGTCTACGAGACCT
HCV RNA (internal) 278 F: GTCTTCACGCAGAAAGCGTCTAGCC
R: CACTCGCAAGCACCCTATCAGGCAG
GABA A α1(external) 241 F: CGGTCAATTTTGCTGACACT
R: GGTTATGCATGGGATGGC
GABA A α1(internal) 95 F: GACCTCTTTAAGGTTCTATGG
R: GCTCCAACAGCAACCAGC
GABA A β3 (external) 319 F: CACATCGGTTAGATCAGG
R: CAAGGCAAAGAATGACCG
GABA A β3 (internal) 110 F: CGCTGGAAGTTCACAATG
R: CGAGGCATGCTCTGTTTC
β-Actin 434 F: CAAAGACCTGTACGCCAACACA
R: AACCGACTGCTGTCACCTTCAC
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purchased from Gene Tex, Inc. The reactions with the goat
antibodies against β-actin, 43 kDa (SC-1615, Santa Cruz
Biotechnology) were carried out at the dilution of 1 to 300.
The bound antibodies were visualized using the enhanced
chemiluminescence (ECL) Western blotting reagent (SC-
2048, Santa Cruz Biotechnology) with signals captured on
film. In order to quantify the density of signals, the Bio-Rad
Quantity One system was used. To estimate the comparative
levels of GABA A α1a n dβ3 subunits expression, all
immunoreactivities were normalized to β-actin expression
before statistical analysis.
The statistical analysis was conducted using Statistica 8.0
PL Software (StatSoft). The results for groups were compared
using the Kruskal–Wallis test and the Mann–Whitney test.
p-values<0.05 were considered to be statistically significant.
Results
mRNAs of both α1 and β3 subunits of GABA A receptor
are expressed in human PBMCs
The presence of mRNAs of α1 and β3 was evaluated in
PBMCs. Cells were collected from healthy donors and
CHC patients who had undergone antiviral treatment.
A c c o r d i n gt ot h eH C VR N As t a t u si ns e r aa n di n
PBMCs, three subgroups of patients were distinguished:
0 / 0w i t hs e r aa n dP B M C sf r e ef r o mH C VR N A( n=10);
0/1 with sera negative for HCV RNA, but with HCV
RNA-positive PBMCs (n=6); and the 1/1 group, where
sera and PBMC samples contained HCV RNA (n=6). To
analyze the gene expression of GABA A receptor subunits
α1a n dβ3, reverse transcription followed by nested PCR
was used. PCR amplification produced single α1- and β3-
specific PCR products, of 95 and 110 bp, respectively. Our
results showed that all PBMC samples contained mRNA
specific for the α1a n dβ3s u b u n i t so fG A B AAr e c e p t o r .
The expression of β-actin was used as the endogenous
control of gene expression. As shown in Fig. 1, the gene
expression of GABA A receptor subunits differs among
PBMC samples, even among the same group. No
significant differences were found in gene expression
level for either α1o rβ3 between groups. We could only
observe that β3 gene expression showed a margin
tendency to be elevated in PBMCs from healthy donors
in comparison to the HCV-infected patients. In contrast,
the gene expression of α1 subunit in PBMCs tends to be
slightly higher in the group of CHC patients compared to
the healthy controls.
Fig. 1 Gamma-aminobutyric
acid type A (GABA A) receptor,
α1 and β3 genes expression in
peripheral blood mononuclear
cells (PBMCs). The figure
shows several examples of the
results obtained by reverse
transcription polymerase chain
reaction (RT-PCR) analysis
performed in the groups as
follows: a healthy donors (HD)
and (b–d) anti-hepatitis C virus
(HCV)-treated chronic hepatitis
C (CHC) patients, who:
b eliminated HCV RNA from
both sera and PBMCs (0/0),
c only from sera (0/1), or d
neither from sera nor from
PBMCs (1/1). As a control of
gene expression, the analysis
of β-actin was performed
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receptor in PBMCs at the protein level
The presence of the protein expression of GABA A α1 and
β3 subunits was confirmed using Western blot in all of the
tested PBMC samples. Figure 2 shows several examples of
Western blot analysis performed on lysates obtained from
the PBMCs of healthy donors and CHC patients. The
quantitative immunoblotting based on a density analysis,
described in the Materials and methods section, was utilized
in order to determine the possible differences in the GABA
A α1 and β3 subunits expression between PBMC samples.
As indicated in Fig. 3a, the GABA A α1 protein expression
was somewhat higher (p=0.047) in the group of anti-HCV-
treated CHC patients than in the group of healthy controls.
However, no statistical differences were found between
individual subgroups of patients.
An opposite relation was found for the expression of β3
subunit. In PBMCs from anti-HCV-treated CHC patients, the
β3 protein showed decreased levels in comparison to the
group of healthy donors. As presented in Fig.3b, significant
differences (p=0.0038) in the β3 expression among healthy
donors and the three subgroups of CHC patients were
observed as a result of the β3 expression analysis. The
lowest expression level of β3 protein, compared to the
healthy donors, was observed in PBMCs from patients, who,
despite the antiviral treatment, have retained HCV RNA in
both sera and PBMCs (p=0.00047).
Discussion
Several studies have revealed the contribution of a variety of
host factors to the development of HCV RNA persistence in
chronically infected patients, despite having used antiviral
treatment [13, 16, 17]. Our study was designed to evaluate
whether the expression of chosen subunits of GABA A
receptors in PBMCs bears any relation to HCV infection and/
Fig. 2 Expression of α1 and
β3 subunits of the GABA A
receptor in PBMCs as revealed
by Western blot analysis.
Representative images of
Western blot analysis come
from groups as follows: a
healthy donors (HD) and
(b–d) anti-HCV-treated CHC
patients, who: b eliminated
HCV RNA from both sera
and PBMCs (0/0), c only from
sera (0/1), or d neither from
sera nor from PBMCs (1/1).
The analysis of β-actin was
performed as a control of
gene expression
1540 Eur J Clin Microbiol Infect Dis (2012) 31:1537–1542or the path of HCV RNA elimination after anti-viral
treatment. Studies that were carried out on other viruses like
herpes simplex virus (HSV) and human immunodeficiency
virus (HIV) indicated that the expression of GABA A
receptor on the target cells could be modulated upon the
viral infection [18, 19]. Although GABA A receptors tend to
exist as a pentameric structure consisting of six major GABA
A receptor subunits [1], we decided to screen the expression
of two of them: α1a n dβ3. This choice was grounded on
Alam et al.’ss t u d y[ 15] that confirmed the significant content
of the α1 subunit in PBMCs and fractionated T-cell
populations. The evaluation of β3 expression, despite the
lower abundance of this subunit in PBMCs, seemed
interesting due to the confirmed impact on a proliferative
activity of other cells [20, 21].
If governing the HCV infection indeed plays any role in
the GABA A receptor activity, the modulation of their
expression would be an expected phenomenon. To address
this issue, we analyzed the α1 and β3 GABA A expression
inPBMCsusingnestedPCRandquantitativeimmunoblotting.
Our results showed, for the first time, that the expression of the
α1a n dβ3 subunits of the GABA A receptor is common not
only for healthy donors (15), but also for anti-HCV-treated
patients. Moreover, the expression of these subunits at the
proteinleveldisplayeddifferencesbetweenhealthydonorsand
CHC patients.A marginally significantelevation of α1 GABA
A in PBMCs was demonstrated for anti-HCV-treated patients
when compared with healthy donors. It seems interesting that
the expressionofα1 GABA A receptor subunit is detectable in
the majority of PBMCs subtypes, such as: T-cells, B-cells, and
monocytes, in other words, in cells that are also able to
maintain HCV during chronic infection [22]. Taking into
account that the increased expression of these receptors in T-
cells downregulates the effector T-cell response [23, 24]a n d
that the defective function of HCV-specific T-cells contribute
to the chronicity of infection [25–27], we can hypothesize
that GABA A activation may contribute to the impaired
response to the HCV infection.
In contrast, the majority of PBMCs from the anti-HCV-
treated patients represented significantly lower expression of
the β3 subunit of the GABA A receptor than the healthy
donors’ PBMCs. Thus, also in case of the β3s u b u n i t ,
expression measured at the protein level does not reflect
precisely the gene expression level. This type of discrepancy,
probably connected with the post-transcriptional regulation,
was observed for GABA A receptor expression previously
[28]. The lowest level of GABA A β3r e c e p t o re x p r e s s i o n
was observed in these PBMCs, where HCV RNA presence
in cells was accompanied by the HCV RNA positivity of
sera. As was demonstrated, the transfection of hepatoma
cells with β3-specific cDNA resulted in a significant
decrease of cell proliferation [29]. Similarly, an increased
GABA A β3 receptor expression was found to act as an
inhibitory signal for hepatic cell proliferation, whereas the
downregulation of the GABA A β3r e c e p t o re x p r e s s i o nw a s
observed in malignant hepatocyte cell lines [4]. Although
less is known about the role of β3 subunit expression of the
GABA A receptor in PBMCs, we can hypothesize that, like
in the case of hepatic cells, the decreased expression of
GABA A β3 receptor in PBMCs may alter the proliferative
activity of these cells. Since HCV-infected cells present
enhanced proliferation in comparison to non-infected cells
[30, 31], this process appears to play an important role in
HCV RNA replication. On the other hand, it was previously
demonstrated that the drug-dependent inhibition of GABA A
receptors expression does not alter HCV load [32], which
may suggest that, rather, HCV infection is responsible for
inducing such changes in GABA A expression that favor
HCV propagation in target cells.
In conclusion, the current study provides evidence for
the α1a n dβ3 expression in PBMCs from HCV-infected
patients. Decreased GABA A β3e x p r e s s i o n ,w h i c hi s
observed in HCV RNA-positive PBMCs, may create a
favorable environment for HCV RNA persistence. Future
studies should elucidate whether the alteration of GABA
A expression, which is observed during CHC infection,
Fig. 3 Differences in GABA A α1 and β3 subunits expression in
PBMCs evaluated by Western blot analysis. The results are shown
after normalization to the β-actin expression. a Relative expression
level of GABA A α1 protein in PBMCs from healthy donors and from
post-treatment CHC patients. b Relative expression level of GABA A
β3 protein expression in PBMCs from healthy donors and three
groups of anti-HCV-treated CHC patients (0/0, 0/1, 1/1)
Eur J Clin Microbiol Infect Dis (2012) 31:1537–1542 1541has an impact on the development of hepatocellular
carcinoma.
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